Clinical trials: Inhalation
Asthma
Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma
The aim of the study is to evaluate efficacy and safety of a 48-week treatment with two doses of tiotropium bromide compared to placebo in adolescent patients with moderate persistent asthma.
- Trial name
- NCT01257230
- Testing
- tiotropium Respimat low dose, tiotropium Respimat high dose
- Where
- 66 sites in United States, Chile and 10 more
- Volunteers
- 398 people
- Sponsor
- Boehringer Ingelheim
Agitation,Psychomotor, Haloperidol Causing Adverse Effects in Therapeutic Use
Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation
The primary objective of this study is to determine the noninferiority of inhaled loxapine compared to intramuscular haloperidol/lorazepam on agitation reduction at 120 minutes.
- Conditions
- Agitation,Psychomotor, Haloperidol Causing Adverse Effects in Therapeutic Use, Lorazepam Causing Adverse Effects in Therapeutic Use, Loxapine Causing Adverse Effects in Therapeutic Use
- Trial name
- loxapine (NCT03110900)
- Testing
- Haloperidol + lorazepam, Loxapine
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- University of Arkansas
Respiratory Distress Syndrome, Adult
Treprostinil Sodium Inhalation for Patients At High Risk for ARDS
Acute Respiratory Distress Syndrome (ARDS) is a rapidly progressing lung disease caused by a number of factors including pneumonia, sepsis and acute trauma that leads to reduced lung function and breathlessness.
- Trial name
- NCT02370095
- Testing
- Treprostinil Inhalation Solution
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of North Carolina, Chapel Hill
Asthma
Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children
This is a Phase IIb, multi-centre, randomised, double-blind, parallel-group, placebo-controlled study in children aged 5-11 years with persistent uncontrolled asthma.
- Trial name
- NCT01573767
- Testing
- Fluticasone propionate 100mcg, Vilanterol
- Where
- 120 sites in United States, Argentina and 12 more
- Volunteers
- 463 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Effect of Inhaled Fentanyl on Dyspnea and Exercise Tolerance in Chronic Obstructive Pulmonary Disease (COPD)
Breathing discomfort (dyspnea) and activity limitation are dominant symptoms of chronic obstructive pulmonary disease (COPD) and contribute to poor health-related quality of life in this population.
- Trial name
- NCT00974220
- Testing
- fentanyl
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- Queen's University
Chronic Obstructive Pulmonary Disease
A Home-based Intervention to Promote Mindful Breathing Awareness Through Pursed-lip Breathing Training for COPD Patients
The Mindful Breathing Laboratory under the direction of Dr. Benzo will complete a randomized controlled trial to evaluate the mindful breathing module.
- Trial name
- NCT05349123
- Testing
- Mindful Breathing, Home-Based Pulmonary Rehabilitation
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Minnesota HealthSolutions
Obstructive Sleep Apnea Syndrome
Brain Oxygenation and Hemodynamics During Sleep in Obstructive Sleep Apnea Sufferers
The goal of this trial is to assess the performance of the OxiplexTS-an absolute near-infrared oximeter-as an instrument to measure brain oxygenation and hemodynamics in sleep medicine as well as in the broader field of…
- Trial name
- NIRS-OSAS (NCT00591591)
- Testing
- OxiplexTS
- Where
- 4 sites in United States
- Volunteers
- 309 people, healthy volunteers welcome
- Sponsor
- ISS, Inc.
Spinal Cord Injuries, Slow Breathing
Slow Yogic-Derived Breathing and Respiration and Cardiovascular Variability in Spinal Cord Injury Patients
This research will aid in understanding of slow-breathing and its effect on heart rate and blood pressure in people with a spinal cord injury (SCI).
- Trial name
- SCOGA (NCT05480618)
- Testing
- Slow Breathing
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Spaulding Rehabilitation Hospital
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Japanese Patients With COPD
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL inhalation solution delivered by the Respimat inhaler once daily for 4 weeks in Japanese patients with chronic obstructive pulmonary disease…
- Trial name
- NCT00824382
- Testing
- BI 1744 CL 2 µg, BI 1744 CL 5 µg, BI 1744 CL 10 µg
- Where
- 48 sites in Japan
- Volunteers
- 328 people
- Sponsor
- Boehringer Ingelheim
Bronchiectasis
Comparative Effectiveness and Safety of Inhaled Corticosteroids and Antimicrobial Compounds for Non-CF Bronchiectasis
The purpose of this study is to provide patients and their physicians with greater understanding of the risks and benefits of commonly used therapies for treatment of non-CF bronchiectasis
- Trial name
- NCT02714283
- Testing
- inhaled corticosteroid therapy, macrolide therapy
- Volunteers
- 90,089 people
- Sponsor
- Oregon Health and Science University
Breast Cancer
Active Breathing Coordinator-based vs VisionRT-based Deep Inspiration Breath-hold for Radiation for Breast Cancer
Female patients treated with radiation for left-sided breast malignancy will undergo alternate fractions of Active Breathing Coordinator (ABC)-assisted and VisionRT-assisted Deep Inspiration Breath-Hold (DIBH).
- Trial name
- VisionRT (NCT02694029)
- Testing
- Active Breathing Coordinator (ABC), VisionRT
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Texas Southwestern Medical Center
Pulmonary Arterial Hypertension
Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension
This study enrolls patients with pulmonary arterial hypertension (PAH) treated with inhaled treprostinil. During the study, the treatment with inhaled treprostinil will be tapered off and simultaneously replaced with an oral…
- Trial name
- TRANSIT-1 (NCT02471183)
- Testing
- Selexipag
- Where
- 15 sites in United States
- Volunteers
- 34 people
- Sponsor
- Actelion
Asthma
MethaCholine Bronchoprovocation Study (MeCIS)
The purpose of this research is to evaluate the methacholine challenge test as an accurate indicator of asthma in patients receiving treatment for asthma.
- Trial name
- MeCIS (NCT00705341)
- Testing
- fluticasone
- Where
- 13 sites in United States
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies
The purpose of the study aims to determine whether different concentrations of nitrous oxide (N2O) have different antidepressant effects for adults with treatment-resistant major depression.
- Trial name
- NARSAD (NCT03283670)
- Testing
- Nitrous Oxide 25%, Nitrous Oxide 50%
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
High Flow Nasal Cannula
HFNC Flow Titration and Effort of Breathing in the PICU
High-flow nasal cannula (HFNC) is a method of non-invasive respiratory support used to decrease the effort of breathing (EOB) in patients with a wide variety of respiratory diseases in the pediatric intensive care unit.
- Trial name
- HFNCandEOB (NCT02793674)
- Testing
- Fisher & Paykel high flow nasal cannula, Vapotherm high flow nasal cannula
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Children's Hospital Los Angeles
Asthma
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
This is a randomised, double-blind, parallel group, placebo-controlled study designed to evaluate the efficacy and safety of a fixed 30 mg dose of benralizumab administered subcutaneously for patients with a history of asthma…
- Trial name
- NCT03186209
- Testing
- Benralizumab
- Where
- 79 sites in China, Philippines and 2 more
- Volunteers
- 695 people
- Sponsor
- AstraZeneca
Asthma
A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma
This study is to assess the safety of an investigational drug in children 4 to 11 years of age who have asthma. The subjects will attend 7 clinic visits, of which up to 3 will be in the morning, and have lung function tests…
- Trial name
- NCT00441441
- Testing
- fluticasone propionate, fluticasone propionate/salmeterol
- Where
- 55 sites in United States, Australia and 11 more
- Volunteers
- 351 people
- Sponsor
- GlaxoSmithKline
Delivery Room Resuscitation
Quantitative End Tidal CO2 Monitoring in the Delivery Room (DR)
This is a trial evaluating the use of an end tidal CO2 monitor during ventilation in the delivery room. The use of the monitor is compared with clinical assessment of ventilation.
- Trial name
- NCT01381068
- Testing
- End tidal CO2 monitor
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Neil Finer
Congenital Heart Disease
Inhaled NO as an Anti-inflammatory and Anti-reperfusion Agent in Infants and Children Undergoing Cardiopulmonary Bypass
Each year, there are over 400,000 cardiac surgical operations performed in the United States; of which 10,000 are performed on children.
- Trial name
- NCT00585013
- Testing
- Nitric Oxide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Washington University School of Medicine
Asthma
Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol Xinafoate Combination Versus Inhaled Corticosteroids or Other Combination Therapy
The objective of this study is to compare healthcare utilization and costs in Medicare-eligible asthma patients (aged >65) who receive fluticasone propionate/salmeterol xinafoate combination or inhaled corticosteroids in a…
- Trial name
- NCT01347060
- Testing
- fluticasone propionate/salmeterol xinafoate combination, inhaled corticosteroids
- Volunteers
- 17,448 people
- Sponsor
- GlaxoSmithKline